BioNTech SE (BNTX)

NASDAQ: BNTX · Real-Time Price · USD

110.23

+1.43 (1.31%)

At close: Feb 27, 2026, 4:00 PM EST

111.00

+0.77 (0.70%)

After-hours: Feb 27, 2026, 6:00 PM EST

Revenue Breakdown

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
COVID-19 Vaccine Revenue (Post-FY2023 Reporting)	2.26B	2.43B	3.78B
COVID-19 Vaccine Revenue (Post-FY2023 Reporting) Growth	-7.01%	-35.59%	-77.98%
Other Sales Revenue (Post-FY2023 Reporting)	277.80M	319.00M	42.80M
Other Sales Revenue (Post-FY2023 Reporting) Growth	-12.91%	645.33%	-74.12%
Revenue (Other)	640.40M	-	-
Revenue (Total)	3.18B	2.75B	3.82B
Revenue (Total) Growth	15.59%	-27.96%	-77.94%

Revenue Breakdown 2

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
COVID-19 Vaccine Revenue (Pre-FY2024 Reporting)	-	-	3.78B
COVID-19 Vaccine Revenue (Pre-FY2024 Reporting) Growth	-	-	-77.98%
Other Sales Revenue (Pre-FY2024 Reporting)	-	-	39.30M
Other Sales Revenue (Pre-FY2024 Reporting) Growth	-	-	-20.45%
Commercial Revenue	-	-	3.82B
Commercial Revenue Growth	-	-	-77.81%
Research & Development Revenue	-	-	3.50M
Research & Development Revenue Growth	-	-	-96.98%
Revenue (Total)	3.18B	2.75B	3.82B
Revenue (Total) Growth	15.59%	-27.96%	-77.94%

Updated Nov 3, 2025. Data Source: Fiscal.ai.